# Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia

Study · id `cardio:ct-nct07827521` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT07827521](<https://clinicaltrials.gov/study/NCT07827521>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT07827521

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 4 trial registered on ClinicalTrials.gov. The registry status is not yet recruiting. It plans to enroll 180 participants.

## Technical summary

Registry record NCT07827521. Randomized; single masking; primary purpose treatment. Start 2026-10-20 (anticipated); primary completion 2028-10-01 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose treatment
- Phase: Phase 4
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT07827521, source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)
- Planned start: 2026-10-20 (anticipated) (ClinicalTrials.gov record NCT07827521, source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)
- Primary completion: 2028-10-01 (anticipated) (ClinicalTrials.gov record NCT07827521, source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)
- Completion: 2029-12-31 (anticipated) (ClinicalTrials.gov record NCT07827521, source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT07827521, source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "NOT\_YET\_RECRUITING" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct07827521-2026-09-18`, retrieved 2026-10-26)

## The registry's words

- Brief title: Seltoplasmid Plus Revascularization for Diabetic Infrapopliteal Chronic Limb-Threatening Ischemia
- Condition: Chronic Limb-Threatening Ischemia
- Condition: Diabetic Foot Ulcer
- Condition: Infrapopliteal Arterial Occlusive Disease
- Intervention (Procedure): Lower-Extremity Revascularization
- Intervention (Genetic): Donaperminogene Seltoplasmid
- Lead sponsor: First Affiliated Hospital of Wenzhou Medical University
- Lead sponsor class: OTHER
- Collaborator: Beijing Northland Biotech. Co., Ltd.
- Collaborator class: INDUSTRY

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry condition terms include this condition: Diabetes mellitus (`core:diabetes-mellitus`)
- Registry lists this organization as the lead sponsor: First Affiliated Hospital of Wenzhou Medical University (`cardio:org-first-affiliated-hospital-of-wenzhou-medical-university`)
- Registry lists this organization as a collaborator: Beijing Northland Biotech. Co., Ltd. (`cardio:org-beijing-northland-biotech-co-ltd`)

## Provenance

Content hash: ca2af17859f925ba5620c1a94c18f837e6ba2169bc630ac591537b5bfefa86a8
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
